Blackstone Life Science and Boston Science have reached a deal worth US$455 million. The two sides will jointly fund the development of a minimally invasive heart pump. The two companies are collaborating to develop the Vitalyst system. It's a device designed by Boston Science to support the heart's pumping without the need for open thoracic surgery. The Vitalyst system was developed to treat cardiogenic shock, a medical emergency caused by the heart not being able to pump enough blood. The deal marks the first time the two companies have teamed up to fund a Boston Scientific product.

Blackstone Life Science and Boston Science have reached a deal worth US$455 million. The two sides will jointly fund the development of a minimally invasive heart pump. The two companies are collaborating to develop the Vitalyst system. It's a device designed by Boston Science to support the heart's pumping without the need for open thoracic surgery. The Vitalyst system was developed to treat cardiogenic shock, a medical emergency caused by the heart not being able to pump enough blood. The deal marks the first time the two companies have teamed up to fund a Boston Scientific product.